CN112694520B - Artificial polypeptide HM, antibody thereof and application thereof in pathological detection - Google Patents
Artificial polypeptide HM, antibody thereof and application thereof in pathological detection Download PDFInfo
- Publication number
- CN112694520B CN112694520B CN202011455246.XA CN202011455246A CN112694520B CN 112694520 B CN112694520 B CN 112694520B CN 202011455246 A CN202011455246 A CN 202011455246A CN 112694520 B CN112694520 B CN 112694520B
- Authority
- CN
- China
- Prior art keywords
- antibody
- artificial polypeptide
- artificial
- polypeptide
- cdr
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56966—Animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention discloses an artificial polypeptide HM, an antibody thereof and application thereof in pathological detection, belonging to the technical field of biological detection and the field of immunology. The polypeptide HM has an amino acid sequence shown in any one of SEQ ID NO 11-20, and the heavy chain variable region CDR-H1, CDR-H2 and CDR-H3 and the light chain variable region CDR-L1, CDR-L2 and CDR-L3 of the monoclonal antibody resisting the artificial polypeptide HM have amino acid sequences shown in SEQ ID NO 37-42 respectively. The artificial polypeptide HM and the antibody thereof are utilized to establish a pathology-enhanced type secondary antibody detection method, the stability is high, the repeatability is good, and the method is particularly suitable for detecting the protein with low expression abundance; good specificity, high sensitivity and wide application prospect.
Description
Technical Field
The invention belongs to the technical field of biological detection and the field of immunology, and particularly relates to an artificial polypeptide HM, an antibody thereof and application thereof in pathological detection.
Background
Immunohistochemistry (IHC) refers to an immunological detection technique in which specific antibodies labeled with color-developing reagents are subjected to antigen-antibody reaction and histochemical color development reaction in situ in tissue cells to qualitatively, quantitatively or locally detect corresponding antigens in pathological tissues. The immunohistochemical detection principle is as follows: after the tissue slice is subjected to antigen heat repairing treatment, incubating the tissue slice with a primary antibody reagent to form an antigen-antibody compound of primary antibody and target antigen in situ; the primary antibody molecule in the antigen-antibody complex is combined with the enzyme-labeled polymer secondary antibody through incubation, and the antigen-antibody-secondary antibody polymer complex is further formed in situ; finally, a coloured deposit is formed at the antigenic site by the enzyme-catalysed substrate. And (4) observing the brown part under an optical microscope to determine whether the target antigen exists and the expression condition of the target antigen. Determining the type and morphology of pathological tissue cells, identifying the source of tissue cell products, and determining the degree of differentiation of tissue cells by immunohistochemical staining; especially, the application in clinical pathology is the most important, such as identifying pathological nature, finding micro-focus, discussing tumor origin or differentiation phenotype, determining tumor stage, and guiding treatment and prognosis; aid in disease diagnosis and classification, search for infection causes, and the like.
At present, the companies supplying the secondary antibody products of the antibody-enzyme labeling-polymer detection system in the domestic market mainly comprise: (1) The Envision secondary antibody of Dako uses chain glucan as a polymer carrier, a plurality of enzyme molecules and secondary antibody molecules are connected on the carrier, so that a detection signal is amplified, but the chain glucan has a large molecular weight, so that the whole enzyme-antibody polymer generates large steric hindrance when being combined with tissue protein, and the detection sensitivity of the protein expressed by low abundance is not high; (2) CN105566499A discloses a pathology enhanced secondary antibody principle, which is an enzyme-labeled secondary antibody prepared by using a grape cluster polymer as a carrier, so that a plurality of enzymes are tightly connected to a spherical multi-branch carrier molecule, belonging to the preparation of a one-step secondary antibody. (3) AmpliStain, invented by Baesweiler, SDT GmbH, germany TM detection systems used serpentine linker crop backbones to prepare enzyme-vector-secondary antibody complexes. (4) The secondary antibody developed by Roche diagnostics is prepared by coupling naturally-occurring small molecule hapten (such as pesticide, veterinary drug, antibiotic, quantum dot, etc.) with antibodyThe existing small molecule hapten is combined with a corresponding enzyme polymer anti-small molecule hapten antibody, so that immunohistochemical detection of tissue protein is realized; however, the method needs natural hapten micromolecules, needs more toxic and harmful chemical reagents in the cross-linking process, and has complex coupling process, so the production cost is higher.
At present, the prior art has no great improvement on polymer structure design and preparation process, and is specifically embodied in that: the number of enzymes and antibodies in unit volume is not obviously increased; the steric hindrance of the polymer is not obviously reduced, so that the sensitivity is not improved, and a pathology detection enhanced secondary antibody with better effect is urgently needed.
Disclosure of Invention
In order to solve the technical problems, the technical scheme adopted by the invention is as follows:
the first aspect of the present invention provides an artificial polypeptide composition comprising at least one of an artificial polypeptide PL, an artificial polypeptide HM and an artificial polypeptide LH, wherein,
the amino acid sequence of the artificial polypeptide PL comprises TTT (PTT) n, wherein n = 1-10, namely the artificial polypeptide PL has an amino acid sequence shown in SEQ ID NO. 1-10. In some embodiments of the invention, to facilitate coupling of the protein, 1 cysteine (C) is added at the N-terminus or C-terminus of the amino acid.
The amino acid sequence of the artificial polypeptide HM comprises AAP (AADAAD) nAAPAAA, wherein n = 1-10, namely the amino acid sequence shown in SEQ ID NO. 11-20. In some embodiments of the invention, to facilitate coupling of the protein, 1 cysteine (C) is added at the N-terminus or C-terminus of the amino acid.
The amino acid sequence of the artificial polypeptide LH comprises GQA (T) nAQ, wherein n = 1-10, namely the artificial polypeptide LH has the amino acid sequence shown in SEQ ID NO. 21-30. In some embodiments of the invention, to facilitate coupling of the protein, 1 cysteine (C) is added at the N-terminus or C-terminus of the amino acid.
In the present invention, the artificial polypeptide is also referred to as a non-natural polypeptide, a synthetic polypeptide or an artificial polypeptide. It does not occur naturally in mammals, especially humans, and thus cross-reactivity can be avoided.
In a second aspect, the present invention provides a monoclonal antibody composition comprising at least one of the monoclonal antibodies against the artificial polypeptide PL, the artificial polypeptide HM and the artificial polypeptide LH of the first aspect of the present invention, respectively. Wherein, the monoclonal antibody is also called monoclonal antibody.
In some embodiments of the invention, the heavy chain variable region CDR-H1, CDR-H2, CDR-H3 and the light chain variable region CDR-L1, CDR-L2, CDR-L3 of the monoclonal antibody against the artificial polypeptide PL have amino acid sequences shown in SEQ ID NO 31-36, respectively. The antibody is a rabbit-derived antibody, can be specifically bound with artificial polypeptide PL, and has EC50 of 9.94ng/mL.
In some embodiments of the invention, the heavy chain variable region CDR-H1, CDR-H2, CDR-H3 and the light chain variable region CDR-L1, CDR-L2, CDR-L3 of the monoclonal antibody against the artificial polypeptide HM have amino acid sequences shown in SEQ ID NO. 37-42, respectively. The antibody is a rabbit-derived antibody, can be specifically bound with artificial polypeptide HM, and has EC50 of 11.6ng/mL.
In some embodiments of the invention, the heavy chain variable region CDR-H1, CDR-H2, CDR-H3 and the light chain variable region CDR-L1, CDR-L2, CDR-L3 of the monoclonal antibody against the artificial polypeptide LH have amino acid sequences shown in SEQ ID NO 43-48, respectively. The antibody is a rabbit-derived antibody, can be specifically combined with artificial polypeptide LH, and has EC50 of 1.78ng/mL.
In a third aspect, the invention provides an artificial polypeptide-antibody conjugate composition, which comprises at least one of an artificial polypeptide PL-antibody conjugate formed by the artificial polypeptide PL and an antibody according to the first aspect of the invention, an artificial polypeptide HM-antibody conjugate formed by the artificial polypeptide HM and an antibody according to the first aspect of the invention, and an artificial polypeptide LH-antibody conjugate formed by the artificial polypeptide LH and an antibody according to the first aspect of the invention, wherein the antibody is polyclonal antibody.
In some embodiments of the invention, the polyclonal antibody is a goat anti-mouse polyclonal antibody or a goat anti-rabbit polyclonal antibody.
In a fourth aspect, the present invention provides a polymer composition comprising at least one of a polymer to which an antigen-binding portion of a mab against artificial polypeptide PL according to the second aspect of the present invention is coupled, a polymer to which an antigen-binding portion of a mab against artificial polypeptide HM according to the second aspect of the present invention is coupled, and a polymer to which an antigen-binding portion of a mab against artificial polypeptide LH according to the second aspect of the present invention is coupled, wherein the polymer is further coupled with a color-developing agent. Thus forming the anti-human polypeptide PL monoclonal antibody-color-developing agent label-polymer, the anti-human polypeptide HM monoclonal antibody-color-developing agent label-polymer or the anti-human polypeptide LH monoclonal antibody-color-developing agent label-polymer.
In some embodiments of the invention, the chromogenic agent is a fluorescein, an enzyme, a metal ion, a quantum dot, or an isotope. In some embodiments of the invention, the enzyme is horseradish peroxidase, alkaline phosphatase, or a beta-glucosidase.
In some embodiments of the invention, the antigen binding portion is selected from the group consisting of a Fab fragment, a Fab 'fragment, a F (ab') 2 fragment, a Fv fragment, a scFv fragment, a Fd fragment, and a single domain antibody. In some embodiments of the invention, the antigen binding portion is a Fab' fragment.
The fifth aspect of the present invention provides the use of the artificial polypeptide composition of the first aspect of the present invention or the combination thereof with the monoclonal antibody composition of the second aspect of the present invention in the preparation of a kit for pathological detection.
In a sixth aspect, the invention provides a kit for use in pathological detection comprising an artificial polypeptide-antibody conjugate composition according to the third aspect of the invention and a polymer composition according to the fourth aspect of the invention.
In some embodiments of the invention, the kit further comprises a primary antibody. The polyclonal antibody in the artificial polypeptide-antibody conjugate can be combined with the monoclonal antibody.
In some embodiments of the invention, the kit further comprises a staining agent and a counterstaining agent. Further, the kit also comprises a sample processing reagent.
In a seventh aspect, the present invention provides a complex comprising a biological sample, a primary antibody, one of the artificial polypeptide-antibody conjugate compositions of the third aspect of the present invention, and one of the polymers of the fourth aspect of the present invention, wherein an antigen-binding portion of a monoclonal antibody on the polymer corresponds to and binds to the artificial polypeptide, a polyclonal antibody on the artificial polypeptide-antibody conjugate binds to the primary antibody, and the primary antibody binds to an antigen on the biological sample.
In the invention, the primary antibody is a monoclonal antibody, and further, the primary antibody is a rabbit monoclonal antibody or a mouse monoclonal antibody. Further, the polyclonal antibody is goat anti-rabbit polyclonal antibody or goat anti-mouse polyclonal antibody. When the primary antibody is a rabbit monoclonal antibody, the polyclonal antibody is a goat anti-rabbit polyclonal antibody; when the primary antibody is a murine monoclonal antibody, the polyclonal antibody is a goat anti-mouse polyclonal antibody.
In some embodiments of the invention, the complex comprises a biological sample, a primary antibody, an artificial polypeptide PL-antibody conjugate, and an anti-artificial polypeptide PL mab-developer label-polymer, the antigen-binding portion of the anti-artificial polypeptide PL mab binds to the artificial polypeptide PL, the polyclonal antibody on the artificial polypeptide PL-antibody conjugate binds to the primary antibody, and the primary antibody binds to an antigen on the biological sample, thereby forming the complex.
In some embodiments of the invention, the complex comprises a biological sample, a primary antibody, an artificial polypeptide HM-antibody conjugate, and an anti-artificial polypeptide HM mab-color agent label-polymer, wherein an antigen-binding portion of the anti-artificial polypeptide HM mab binds to the artificial polypeptide HM, a polyclonal antibody on the artificial polypeptide HM-antibody conjugate binds to the primary antibody, and the primary antibody binds to an antigen on the biological sample, thereby forming the complex.
In some embodiments of the invention, the complex comprises a biological sample, a primary antibody, an artificial polypeptide LH-antibody conjugate, and an anti-artificial polypeptide LH-mab-color-developer-labeled-polymer, wherein an antigen-binding portion of the anti-artificial polypeptide LH-mab binds to the artificial polypeptide LH, a polyclonal antibody on the artificial polypeptide LH-antibody conjugate binds to the primary antibody, and the primary antibody binds to an antigen on the biological sample, thereby forming the complex.
The invention has the advantages of
Compared with the prior art, the invention has the following beneficial effects:
the artificial polypeptide sequence of the invention is completely designed artificially, is a sequence which does not exist in the body of a mammal, is produced by a chemical synthesis method, and has good stability and low cost.
The antibody produced by using the artificial polypeptide immunity of the invention can not generate non-specific reaction signals with samples of mammal sources, such as tissues, but only can generate signals by reacting with the artificial polypeptide, so that the antibody can be used for a secondary antibody detection system to avoid generating non-specific signals, and has better specificity.
The pathology enhanced type secondary antibody detection method is established based on the specific combination of the antigen, the primary antibody, the secondary antibody and the polymer secondary antibody, has good stability and repeatability, is particularly suitable for detecting the protein with low expression abundance in immunohistochemistry, and effectively improves the sensitivity and specificity of detection.
Different artificial polypeptides are used for labeling different monoclonal antibodies-enzyme labeling-polymers and then matched with different substrate color development liquids, and different artificial polypeptides and specific antibodies thereof are combined for use, so that double dyeing or multiple dyeing can be realized, a plurality of index detection results can be provided in the same experiment, and the judgment is more accurate.
The invention can also be applied to detection in aspects of ELISA, western blot, immunocytochemistry and the like, and has good specificity, high sensitivity and wide application prospect.
The artificial polypeptide and the antibody thereof prepared by the invention can realize signal amplification in pathological diagnosis, more toxic and harmful chemical reagents are avoided in the preparation process, the coupling process is simple, and the mass production is easy.
Drawings
Figure 1 shows a schematic for detection using an artificial polypeptide-enhanced secondary antibody. A: single antigen detection, B: both antigens were detected simultaneously.
Figure 2 shows the artificial polypeptide PL and its antibody ELISA binding curve.
FIG. 3 shows the binding curve of the artificial polypeptide HM and its antibody ELISA.
Fig. 4 shows the binding curve of the artificial polypeptide LH and its antibody ELISA.
FIG. 5 shows the results of goat anti-mouse, goat anti-rabbit polyclonal antibody titer ELISA.
FIG. 6 shows the results of identifying purified goat anti-mouse and goat anti-rabbit by reducing SDS-PAGE. The protein loading was 10. Mu.g, and lane 1 was goat anti-rabbit IgG. Lane 2 is goat anti-mouse Ig.
FIG. 7 shows the result of Western blot identification of mouse immunoglobulin subtype recognized by goat anti-mouse polyclonal antibodies.
Figure 8 shows that goat anti-rabbit polyclonal antibodies recognize rabbit IgG subclasses.
FIG. 9 shows the binding curves of the artificial polypeptide PL-goat anti-mouse antibody conjugate and anti-PL mab ELISA.
FIG. 10 shows the binding curves of the artificial polypeptide PL-goat anti-rabbit antibody conjugate and anti-PL mab ELISA.
FIG. 11 shows the binding curves of the artificial polypeptide HM-goat anti-mouse antibody conjugate and anti-HM monoclonal antibody ELISA.
FIG. 12 shows the binding curves of the artificial polypeptide HM-goat anti-rabbit antibody conjugate and anti-HM monoclonal antibody ELISA.
FIG. 13 shows the binding curve of the artificial polypeptide LH-goat anti-mouse antibody conjugate and anti-LH monoclonal antibody ELISA.
FIG. 14 shows the ELISA binding curve of the artificial polypeptide LH-goat anti-rabbit antibody conjugate and the anti-LH monoclonal antibody.
Fig. 15 shows the results of the identification of anti-human polypeptide PL antibody-enzyme-labeled-polymer.
FIG. 16 shows the results of the identification of anti-human polypeptide HM antibody-enzyme-labeled-polymer.
Fig. 17 shows the results of the identification of anti-human polypeptide LH antibody-enzyme-labeled-polymer.
Fig. 18 shows the results of immunohistochemical staining of artificial polypeptide PL and its antibodies in the esophagus. Left: the pathology enhanced secondary antibody of the invention has an immunohistochemical staining pattern on esophageal tissue; and (3) right: immunohistochemical staining pattern of control secondary antibody on esophageal tissue.
Fig. 19 shows a comparison of immunohistochemical staining of artificial polypeptide PL and its antibodies on tonsils. Left: the pathology enhanced secondary antibody of the invention has an immunohistochemical staining pattern on tonsil tissues; and (3) right: immunohistochemical staining pattern of control secondary antibody on tonsil tissue.
FIG. 20 is a graph showing a comparison of the kidney immunohistochemical staining of the artificial polypeptide HM and its antibody. Left: the pathology enhanced secondary antibody of the invention has an immunohistochemical staining pattern on kidney tissues; and (3) right: immunohistochemical staining pattern of control secondary antibody on kidney tissue.
Fig. 21 shows a comparison of thyroid immunohistochemical staining for artificial polypeptide LH and its antibodies. Left: immunohistochemical staining patterns of the pathologically enhanced secondary antibodies of the invention on thyroid tissue; and (3) right: immunohistochemical staining pattern of control secondary antibody on thyroid tissue.
Fig. 22 shows the cervical cell smear double stain results. A: p16/Ki-67 double-staining positive result; b: p16/Ki-67 double staining negative results.
FIG. 23 is a graph showing the identification of p63/CK5 double staining of prostate tissue using HM, LH artificial polypeptide and its antibody enzyme-labeled polymer.
Fig. 24 shows triple staining of kidney tissue with PL, LH, HM artificial polypeptides and their fluorescently labeled polymers with antibodies.
Figure 25 shows the use of pathologically enhanced secondary antibodies composed of artificial polypeptides and antibodies thereto in immunocytochemistry applications. A: detecting Raji cells by using the artificial polypeptide HM and the antibody thereof; b: detecting Daudi cells by using the artificial polypeptide PL and an antibody thereof; c: detecting Hela cells by using the artificial polypeptide LH and the antibody thereof.
Detailed Description
In order to make the technical problems, technical solutions and advantageous effects solved by the present invention more apparent, the present invention is further described in detail below with reference to the following embodiments.
Examples
The following examples are used herein to demonstrate preferred embodiments of the invention. It will be appreciated by those of skill in the art that the techniques disclosed in the examples which follow represent techniques discovered by the inventor to function in the invention, and thus can be considered to constitute preferred modes for its practice. Those of skill in the art should, in light of the present disclosure, appreciate that many changes can be made in the specific embodiments which are disclosed and still obtain a like or similar result without departing from the spirit or scope of the invention.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs and the disclosures and materials cited therein are hereby incorporated by reference.
Those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, many equivalents to the specific embodiments of the invention described herein. Such equivalents are intended to be encompassed by the following claims.
The experimental procedures in the following examples are conventional unless otherwise specified. The instruments used in the following examples, unless otherwise specified, were all conventional laboratory instruments; the test materials used in the following examples were purchased from a conventional biochemical reagent store unless otherwise specified.
Example 1 preparation of enhanced Secondary antibody System Using Artificial Polypeptides
The embodiment provides a method for preparing an enhanced secondary antibody by using an artificial polypeptide and application thereof in pathological detection.
Firstly, preparing artificial polypeptide, wherein the artificial polypeptide sequence is completely designed and synthesized by human, and the design principle is as follows: sequences that do not naturally occur in mammals and which produce antibodies that do not specifically cross-react with proteins on mammals, particularly human tissues.
Secondly, preparing a polyclonal antibody aiming at the primary antibody, and coupling the polyclonal antibody with the artificial polypeptide to form an artificial polypeptide-antibody conjugate, namely a primary antibody post-reagent. A polyclonal antibody can be coupled with a plurality of artificial polypeptides, thereby playing a role in amplifying a detection signal.
Then, preparing the anti-human polypeptide monoclonal antibody or antigen binding part thereof, and coupling with the polymer and the color-developing agent to form the anti-human polypeptide antibody-color-developing agent labeled-polymer, wherein the polymer can be combined with a plurality of color-developing agent molecules, thereby playing the role of amplifying the detection signal again. Meanwhile, a plurality of anti-human polypeptide antibodies or antigen binding parts thereof can be bound on the polymer, so that sensitivity can be provided.
In the using process, as shown in fig. 1A, first, primary antibody is used for combining with antigen, then the artificial polypeptide-antibody conjugate is combined with the primary antibody, then the artificial polypeptide is identified by the anti-artificial polypeptide antibody-color reagent label-polymer, and the detection is completed through color reaction. The detection sensitivity can be improved by multiple amplification of the artificial polypeptide and the polymer, and the method is particularly suitable for detection of low-abundance antigen to be detected.
Aiming at the detection of two or more antigens, different artificial polypeptide-antibody conjugates can be prepared by using different polypeptides, and corresponding anti-artificial polypeptide antibody-color reagent labeled-polymer can be prepared, and the simultaneous detection of two or even more antigens can be realized by changing the type of the color reagent.
For example, as shown in fig. 1B, two different antigens are targeted: the first antigen and the second antigen can adopt two different obvious agents to complete double staining, thereby achieving the purpose of simultaneous detection. Specifically, the method comprises the following steps:
primary antibody incubation: first, a first primary antibody capable of specifically binding to a first antigen and a second primary antibody capable of specifically binding to a second antigen are dripped onto a tissue sample, separately or simultaneously.
Primary antibody post-incubation: separately or simultaneously adding a first artificial polypeptide-first multi-antibody conjugate (first post-primary-antibody reagent) and a second artificial polypeptide-second multi-antibody conjugate (second post-primary-antibody reagent).
And (3) secondary antibody incubation: an anti-first artificial polypeptide antibody-first chromogenic tag-polymer (first secondary antibody) and an anti-second artificial polypeptide antibody-second chromogenic tag-polymer (second secondary antibody) are added separately or simultaneously.
Because the colors of the first color developing agent and the second color developing agent or other detection display results are different, the simultaneous detection of the two antigens can be completed.
The first primary antibody and the second primary antibody are both monoclonal antibodies, and the first primary antibody can only be combined with the first antigen and can not be combined with the second antigen; likewise, the secondary antibody is only able to bind to the secondary antigen and not to the primary antigen.
The first multi-antibody can only be combined with the first primary antibody and can not be combined with the second primary antibody; similarly, the second polyclonal antibody can only bind to the second primary antibody and not to the first primary antibody. Of course, the first polyclonal antibody and the second polyclonal antibody can be the same, but cannot be added simultaneously, namely, excessive first polyclonal antibody is added after the excessive first polyclonal antibody is removed, the excessive first polyclonal antibody is added, the second polyclonal antibody is added after the excessive first polyclonal antibody is removed, and then the second polyclonal antibody is added, so that the same purpose can be achieved.
An anti-first artificial polypeptide antibody binds only to the first artificial polypeptide and not to the second artificial polypeptide; similarly, an antibody directed against the second artificial polypeptide will only bind to the second artificial polypeptide and will not bind to the first artificial polypeptide.
By using the same principle and method, a primary anti-post reagent and a secondary anti-post reagent for simultaneously detecting three or more antigens can be prepared, so that the simultaneous detection of three or more antigens is completed.
Example 2 Artificial Polypeptides
The term "artificial polypeptide" as used in this embodiment refers to a polypeptide that does not naturally occur in a mammalian body, and particularly does not occur in human tissue.
An artificial polypeptide PL: the amino acid sequence is TTT (PTT) n, n = 1-10, namely:
TTTPTT(SEQ ID NO:1)，
TTTPTTPTT(SEQ ID NO:2)，
TTTPTTPTTPTT(SEQ ID NO:3)，
TTTPTTPTTPTTPTT(SEQ ID NO:4)，
TTTPTTPTTPTTPTTPTT(SEQ ID NO:5)，
TTTPTTPTTPTTPTTPTTPTT(SEQ ID NO:6)，
TTTPTTPTTPTTPTTPTTPTTPTT(SEQ ID NO:7)，
TTTPTTPTTPTTPTTPTTPTTPTTPTT(SEQ ID NO:8)，
TTTPTTPTTPTTPTTPTTPTTPTT (SEQ ID NO: 9), or
TTTPTTPTTPTTPTTPTTPTTPTTPTTPTTPTT(SEQ ID NO:10)，
To facilitate coupling of the protein, 1 cysteine (C) may be added at the N-terminus or C-terminus of the amino acid.
Artificial polypeptide HM: the amino acid sequence is AAP (AADAAD) nAAPAAA, and n = 1-10, namely:
AAPAADAADAAPAAA(SEQ ID NO:11)，
AAPAADAADAADAADAAPAAA(SEQ ID NO:12)，
AAPAADAADAADAADAADAADAAPAAA(SEQ ID NO:13)，
AAPAADAADAADAADAADAADAADAADAAPAAA(SEQ ID NO:14)，
AAPAADAADAADAADAADAADAADAADAADAADAAPAAA(SEQ ID NO:15)，
AAPAADAADAADAADAADAADAADAADAADAADAADAADAAPAAA(SEQ ID NO:16)，
AAPAADAADAADAADAADAADAADAADAADAADAADAADAADAADAAPAAA(SEQ ID NO:17)，
AAPAADAADAADAADAADAADAADAADAADAADAADAADAADAADAADAADAAPAAA(SEQ ID NO:18)，
<xnotran> AAPAADAADAADAADAADAADAADAADAADAADAADAADAADAADAADAADAADAADAAPAAA (SEQ ID NO: 19), </xnotran>
AAPAADAADAADAADAADAADAADAADAADAADAADAADAADAADAADAADAADAADAADAADAAPAAA(SEQ ID NO:20)。
For ease of coupling to the protein, 1 cysteine (C) may also be added at the N-terminus or C-terminus of the amino acid.
An artificial polypeptide LH: the amino acid sequence is GQA (T) nAQ, and n = 1-10, namely:
GQATAQQ(SEQ ID NO:21)，
GQATTAQQ(SEQ ID NO:22)，
GQATTTAQQ(SEQ ID NO:23)，
GQATTTTAQQ(SEQ ID NO:24)，
GQATTTTTAQQ(SEQ ID NO:25)，
GQATTTTTTAQQ(SEQ ID NO:26)，
GQATTTTTTTAQQ(SEQ ID NO:27)，
GQATTTTTTTTAQQ(SEQ ID NO:28)，
GQATTTTTTTTAQQ (SEQ ID NO: 29), or
GQATTTTTTTTTTAQQ(SEQ ID NO:30)。
For ease of coupling to the protein, 1 cysteine (C) may also be added at the N-terminus or C-terminus of the amino acid.
EXAMPLE 3 preparation of anti-human polypeptide antibodies
Rabbit-derived monoclonal antibodies were further prepared by immunizing rabbits with the artificial polypeptide PL (TTTPTTPTT) of example 2. The antibody can specifically bind to the artificial polypeptide PL, the ELISA binding curve is shown in FIG. 2, and the EC50 is 9.94ng/mL.
The anti-human polypeptide PL antibody is analyzed by using Kabat online software, and the result shows that the variable region sequence of the antibody has the following information:
(1) The CDR-H1 amino acid sequence includes: TNAMS (SEQ ID NO: 31).
(2) The CDR-H2 amino acid sequence includes: IISSSGTYYRWAKG (SEQ ID NO: 32).
(3) The CDR-H3 amino acid sequence includes; GNI (SEQ ID NO: 33).
(4) The CDR-L1 amino acid sequence includes: QSSQSVYNNLA (SEQ ID NO: 34).
(5) The CDR-L2 amino acid sequence includes: RASKLAS (SEQ ID NO: 35).
(6) The CDR-L3 amino acid sequence includes: LGGYDCSSADCGA (SEQ ID NO: 36).
Using the same procedure, rabbits were immunized with the artificial polypeptide HM (AAPAADAAADAAPAAA) obtained in example 2 to prepare further rabbit-derived mabs. The antibody can specifically bind to the artificial polypeptide HM, the ELISA binding curve is shown in figure 3, and the EC50 is 11.6ng/mL.
The anti-human polypeptide HM antibody is analyzed by using Kabat online software, and the result shows that the variable region sequence of the antibody has the following information:
(1) The CDR-H1 amino acid sequence includes: SYAMG (SEQ ID NO: 37).
(2) The CDR-H2 amino acid sequence includes: IATTGSSTYHASWAKG (SEQ ID NO: 38).
(3) The CDR-H3 amino acid sequence includes; DGDWTGWYFSI (SEQ ID NO: 39).
(4) The CDR-L1 amino acid sequence includes: QASQSRNLA (SEQ ID NO: 40).
(5) The CDR-L2 amino acid sequence includes: DASDLAS (SEQ ID NO: 41).
(6) The CDR-L3 amino acid sequence includes: QQGYGGDNIENL (SEQ ID NO: 42).
Using the same method, rabbit-derived monoclonal antibody was further prepared by immunizing rabbit with the artificial polypeptide LH (GQATAQ) of example 2. The antibody can specifically bind to the artificial polypeptide LH, the ELISA binding curve is shown in FIG. 4, and the EC50 is 1.78ng/mL.
The anti-human polypeptide LH antibody is analyzed by using Kabat online software, and the result shows that the variable region sequence of the antibody has the following information:
(1) The CDR-H1 amino acid sequence includes: RYAMC (SEQ ID NO: 43).
(2) The CDR-H2 amino acid sequence includes: IIGVGSGTTYYTSWAKG (SEQ ID NO: 44).
(3) The CDR-H3 amino acid sequence includes; VMPGYDDYGDDDGFDP (SEQ ID NO: 45).
(4) The CDR-L1 amino acid sequence includes: QASEDIYSNLA (SEQ ID NO: 46).
(5) The CDR-L2 amino acid sequence includes: AASYLAS (SEQ ID NO: 47).
(6) The CDR-L3 amino acid sequence includes: QCTYSGSYELFT (SEQ ID NO: 48).
It is worth noting that although the monoclonal antibody is generated for one of the artificial polypeptide sequences, the generated epitopes are concentrated on several identical amino acids, all amino acids having the same epitope can be recognized, and the affinities are not significantly different.
It can be known that the artificial polypeptide antibody prepared in the embodiment is combined with the corresponding artificial polypeptide amino acid sequence with high sensitivity and high specificity, and can be applied to various pathological detections, such as pathological detection by using ELISA, western blot, immunocytochemistry, and the like.
Example 4 purification and characterization of goat anti-mouse Ig and goat anti-rabbit IgG
The goat is immunized by using mouse immunoglobulin (Ig) complex and rabbit IgG respectively to obtain goat anti-mouse or goat anti-rabbit polyclonal antiserum. The serum titer of goat anti-mouse IgG (EC 50) was 1:1950000 serum titers (EC 50) of goat anti-rabbit IgG were 1:3550000. the results of the ELISA curve are shown in FIG. 5.
The Protein A purification is carried out on 2 polyclonal antibodies respectively, and the purification steps are as follows:
(1) Adding equal volume of 2 × Binding Buffer into goat anti-mouse or goat anti-rabbit polyclonal antiserum to be purified, and mixing uniformly for later use.
(2) A new Protein A column is vertically fixed, and a Binding Buffer with the same volume is added according to the volume of the required column. Resuspending Protein A filler, sucking the filler suspension with the required column volume into the column, covering a gasket, adding 30CV deionized water to wash the host, adding 30CV Binding Buffer to balance the column, and adjusting the flow rate of the free flow column to be 1mL/min.
(3) The Protein A column was taken out from 4 ℃ and fixed on a free-flowing plastic rack, and was used after returning to room temperature.
(4) When the alcohol in the column descends to the surface of the upper gasket, 30CV of deionized water is added for washing the column, then 30CV of Binding Buffer balance column is added, and then 30CV of Binding Buffer balance column is added and the flow rate of the free-flowing column is adjusted to be 1mL/min. Multiple antiserum samples were loaded at room temperature at a loading rate of 1mL/min and flow-through samples were collected.
(5) The flow-through solution is concentrated by ultrafiltration and replaced by PBS buffer, and the flow-through solution is placed at 4 ℃ for standby after the concentration is detected.
The purified goat anti-mouse and goat anti-rabbit polyclonal antibodies are respectively identified by reduced SDS-PAGE, the identification result is shown in figure 6, and from figure 6, the reduced SDS-PAGE heavy chain used by the goat anti-mouse Ig polyclonal antibody and the goat anti-rabbit IgG polyclonal antibody is 50kD, the light chain is about 25kD, and the target band is correct.
Purified goat anti-mouse polyclonal antibodies were run on SDS-PAGE reduced with 5 subtypes of monoclonal antibodies IgG1, igG2a, igG2b, igG3, and IgM, respectively, and then transferred to membranes for Western blot detection. The primary antibody is goat anti-mouse purified polyclonal antibody, the secondary antibody is donkey anti-goat marked HRP, a gel imager is used for photographing after color development is carried out by using a color development solution, the identification result is shown in figure 7, and from figure 7, the goat anti-mouse polyclonal antibody recognizable mouse immunoglobulin is respectively IgG1, igG2a, igG2b, igG3 and IgM, and 5 subtypes are provided in total.
Coating an enzyme label plate with immunogen (purified rabbit IgG) for the goat anti-rabbit purified polyclonal antibody, sealing with 5% skimmed milk powder, diluting the goat anti-rabbit purified polyclonal antibody by 4 times from 1 microgram/mL, taking 7 gradients as primary antibody, adding the enzyme label plate with HRP-labeled donkey anti-goat IgG as secondary antibody, carrying out color reaction on TMB, and carrying out 1 MH 2 The plates were read after the termination reaction with SO 4. The ELISA test results are shown in FIG. 8, and it is understood from FIG. 8 that goat anti-rabbit IgG recognizesRabbit IgG subclass, and ELISA four parameter fit curve EC50 is 9.63ng/mL.
Example 5 Artificial polypeptide-labeled antibody or antibody fragment
The artificial polypeptide PL, HM or LH is used as a conjugate of a polyclonal antibody and is coupled with goat anti-mouse Ig and goat anti-rabbit IgG, wherein the goat anti-mouse Ig comprises a mixture of immunoglobulin subclasses such as IgG1, igG2a, igG2b, igG3, igM and the like. Polyclonal antibodies include the full length of an antibody or antigen-binding portion thereof, wherein the antigen-binding portion includes F (ab ') 2, fab', scFv, and the like.
Taking the coupling of the artificial polypeptide PL and the goat anti-rabbit IgG as an example:
(1) After goat anti-rabbit IgG is primarily purified by protein A, the goat anti-rabbit IgG is respectively subjected to Mouse IgG, rat IgG and Human IgG affinity chromatography columns, eluent is collected, and the eluent is dissolved in 5mM EDTA with a certain volume after the concentration is detected by OD 280.
(2) Sulf-SPDP is dissolved in a certain amount of DMSO, and then 1 XPBS solution is added to mix evenly.
(3) Slowly adding the Sulf-SPDP solution into the goat anti-rabbit IgG solution, stirring while adding, uniformly mixing, and standing at room temperature for 1h for activation.
(4) After 1h, the activated goat anti-rabbit IgG solution was filled into a cooled dialysis bag, placed into 2L of pre-cooled 1 XPBS solution, and dialyzed on a magnetic stirrer for 1h at 4 ℃.
(5) After 1h, 2L of fresh 1 XPBS dialysate is replaced, and the solution is dialyzed for 2h at 4 ℃; after 2h, 2L of fresh 1 XPBS dialysate was replaced and dialyzed at 4 ℃ for 2h.
(6) Dissolving artificial polypeptide PL with the same mass as the goat anti-rabbit IgG in a proper amount of DMSO, adding 1 XPBS, quickly mixing uniformly, immediately adding 1mL of activated and dialyzed goat anti-rabbit IgG solution, mixing uniformly, and performing cross-linking reaction at 4 ℃ overnight.
(7) The next day, dialyzing at 4 deg.C for 6 hr, and changing the solution 2-3 times. After dialysis, the vials were filled and stored at-20 ℃.
EXAMPLE 6 identification of conjugates
And (3) identifying the conjugate by adopting an ELISA method:
the artificial polypeptide PL/HM/LH-goat-anti-mouse or goat-anti-rabbit antibody conjugate prepared in example 5 was used to coat the ELISA plate at 1. Mu.g/mL, 50. Mu.L/well overnight at 4 ℃. The next day, after washing the plates, they were blocked with 5% skimmed milk powder at 100. Mu.L/well for 1h at 30 ℃. Rabbit monoclonal antibody resisting the artificial polypeptide PL with different concentration gradients as a primary antibody, 50 mu L/well, and incubation for 1h at 30 ℃. Goat anti-rabbit IgG-labeled HRP was used as a secondary antibody, 50. Mu.L/well, and incubated at 30 ℃ for 40min. After color development with TMB developing solution, the reaction was terminated with 1M sulfuric acid, and the OD450 value was read at the microplate reader.
The detection result of the artificial polypeptide PL-goat anti-mouse or goat anti-rabbit antibody conjugate indirect ELISA is shown in figure 9 and figure 10. The results in FIG. 9 show that: the artificial polypeptide PL-goat anti-mouse antibody conjugate and the anti-human polypeptide PL monoclonal antibody have an immune color reaction, the ELISA binding curve EC50 of the goat anti-mouse coupled with the artificial polypeptide PL and the anti-human polypeptide PL monoclonal antibody is 12ng/mL, the ELISA binding curve EC50 of the goat anti-mouse coupled with the anti-human polypeptide PL monoclonal antibody before coupling is 9.94ng/mL, the EC50 after coupling is 83% of the EC50 before coupling, and the loss of the binding activity is less. The results also indicate that the artificial polypeptide PL is successfully coupled to the goat anti-mouse antibody. The results in FIG. 10 show that: the artificial polypeptide PL-goat anti-rabbit antibody conjugate and the anti-human polypeptide PL monoclonal antibody have an immune color development reaction, the ELISA binding curve EC50 of the goat anti-mouse conjugated with the artificial polypeptide PL and the anti-human polypeptide PL monoclonal antibody is 11.5ng/mL, the ELISA binding curve EC50 of the goat anti-mouse conjugated with the artificial polypeptide PL and the anti-human polypeptide PL monoclonal antibody before conjugation is 9.94ng/mL, the EC50 after conjugation is 86% of the EC50 before conjugation, and the loss of binding activity is less. The result also shows that the artificial polypeptide PL is successfully coupled on the goat anti-rabbit antibody. The obtained artificial polypeptide PL-goat anti-mouse antibody conjugate and the artificial polypeptide PL-goat anti-rabbit antibody conjugate can be prepared into a primary anti-post reagent.
The detection result of the indirect ELISA of the artificial polypeptide HM-goat anti-mouse or goat anti-rabbit antibody conjugate is shown in the figures 11 and 12. The results in FIG. 11 show that: the artificial polypeptide HM-goat anti-mouse antibody conjugate has an immune color reaction with the anti-artificial polypeptide HM monoclonal antibody, the ELISA binding curve EC50 of the goat anti-mouse and anti-artificial polypeptide HM monoclonal antibody coupled by the artificial polypeptide HM is 13.8ng/mL, the ELISA binding curve EC50 of the goat anti-mouse and anti-artificial polypeptide HM monoclonal antibody before coupling is 11.6ng/mL, the EC50 after coupling is 84% of the EC50 before coupling, and the loss of binding activity is less. The result also shows that the artificial polypeptide HM is successfully coupled on the goat anti-mouse antibody. The results in FIG. 12 show that: the artificial polypeptide HM-goat anti-rabbit antibody conjugate has an immune color reaction, the EC50 is 12.6ng/mL, the ELISA binding curve EC50 of the artificial polypeptide HM-goat anti-rabbit antibody conjugate before conjugation is 11.6ng/mL, the EC50 after conjugation is 92% of the EC50 before conjugation, and the loss of binding activity is less. The result also shows that the artificial polypeptide HM is successfully coupled on the goat anti-rabbit antibody. The obtained artificial polypeptide HM-goat anti-mouse antibody conjugate and the artificial polypeptide HM-goat anti-rabbit antibody conjugate can be prepared into a primary anti-post reagent.
The detection result of the artificial polypeptide LH-goat anti-mouse or goat anti-rabbit antibody conjugate indirect ELISA is shown in the figure 13 and figure 14. The results in FIG. 13 show that: the artificial polypeptide LH-goat anti-mouse antibody conjugate has an immune color development reaction with the anti-artificial polypeptide LH monoclonal antibody, the ELISA binding curve EC50 of the goat anti-mouse conjugated with the artificial polypeptide LH and the anti-artificial polypeptide LH monoclonal antibody is 4.81ng/mL, the ELISA binding curve EC50 of the goat anti-mouse conjugated with the artificial polypeptide LH and the anti-artificial polypeptide LH monoclonal antibody before coupling is 1.78ng/mL, and the binding EC50 of the antigen antibody after coupling is still sensitive. The result also shows that the artificial polypeptide LH is successfully coupled on the goat anti-rabbit antibody. The results in FIG. 14 show that: the artificial polypeptide LH-goat anti-mouse or goat anti-rabbit antibody conjugate has an immune color reaction, the EC50 is 3.23ng/mL, the ELISA binding curve EC50 before conjugation is 1.78ng/mL, although the EC50 after conjugation is 55% of the EC50 before conjugation, the antigen-antibody binding EC50 after conjugation is more sensitive. The result also shows that the artificial polypeptide LH is successfully coupled on the goat anti-rabbit antibody. The obtained artificial polypeptide LH-goat anti-mouse antibody conjugate and the artificial polypeptide LH-goat anti-rabbit antibody conjugate can be prepared into a primary anti-post reagent.
Example 7 preparation of anti-human polypeptide antibody-developer-labeled-Polymer
The color developing agent of the present embodiment is exemplified by horseradish peroxidase (HRP).
(1) Activation of 50mg horseradish peroxidase (dissolved in 0.01M PBS (pH7.4) at 5mM EDTA, 25 mg/mL) using Sulf-SMCC for 30min at room temperature, at a molar ratio of 20-40, 10kD, for subsequent ultrafiltration concentration, was performed.
(2) S-acetylmercaptosuccinic anhydride is used to activate polymer carrier (molecular weight is 7W-12W) (the polymer carrier is dissolved in 0.01M PBS solution with pH value of 6.5. The reaction mixture is ultrafiltered and concentrated by a 50kD ultrafilter tube, the buffer solution is replaced to 0.01M PBS with pH value of 7.4. The collected solution is ultrafiltered and concentrated, and the collected solution is preserved at 4 ℃ for standby.
(3) Mixing the products obtained in the step (1) and the step (2), and reacting for 16-20h at 4 ℃. 0.1M mercaptoethanol was added to the reaction mixture in an amount of 1/10 by volume, and the reaction was carried out at 30 ℃ for 20min. This step produces a polymeric carrier-enzyme complex.
(4) The reaction product in step (3) was purified using a Sephadex G-200 column, and the solution at a high molecular weight at 403nm was collected and concentrated to about 3mL by ultrafiltration. This step produces a polymeric carrier-enzyme complex.
(5) The anti-artificial polypeptide PL antibody/anti-artificial polypeptide HM antibody/anti-artificial polypeptide LH antibody is digested by pepsin, and the digestion buffer solution is a citric acid buffer solution with the pH value of 3.2. The enzyme is cut at 37 ℃ for 2-3h to prepare F (ab') 2. Adding a proper amount of 0.1M cysteamine hydrochloride into the prepared F (ab ') 2, reacting for 1.5h at the temperature of 37 ℃, wherein the molar mass ratio of the cysteamine hydrochloride to the antibody F (ab') 2 is 100.
(6) Taking a proper amount of polymer carrier-enzyme complex prepared by activation of Sulf-SMCC, and reacting for 30min at room temperature. Ultrafiltering and concentrating with 50kD ultrafiltering tube, and replacing buffer solution with 0.01M PBS (pH7.4); fractions at 403nm were collected.
(7) And (4) mixing the compound obtained in the step (6) with anti-artificial polypeptide PL monoclonal antibody/anti-artificial polypeptide HM antibody/anti-artificial polypeptide LH antibody Fab', and reacting for 16-20h at 4 ℃. After the reaction is finished, adding a proper volume of 0.1M mercaptoethanol, and reacting for 20min at 30 ℃; the synthesized reaction mixture was then purified on Sephadex G-200 molecular sieves.
The absorbance was measured at 280nm and 403nm, respectively, and the results are shown in FIG. 15, FIG. 16 and FIG. 17.
Fig. 15 to 17 show the results of identification of anti-human polypeptide PL antibody-enzyme-labeled polymer, anti-human polypeptide HM antibody-enzyme-labeled polymer, and anti-human polypeptide LH antibody-enzyme-labeled polymer, respectively, in which the high molecular weight filtrate component having two peaks is the corresponding polymer, and a secondary antibody can be prepared.
Example 8 application of the pathologically enhanced Secondary antibody IHC detection method
The IHC detection method is as follows:
(1) Paraffin-embedded human tissue sections (experimental group and control group) were selected for deparaffinization and hydration, respectively.
(2) Using Tris-EDTA, pH9.0 antigen repairing buffer solution, boiling the tissue antigen at high temperature and normal pressure for 15-20min to repair. After 15-20min, the fire is turned off, and the tissue slices are kept in the antigen retrieval buffer solution to be cooled to room temperature.
(3) The slices cooled to room temperature were rinsed 3 times with tap water for 10-30 seconds each.
(4) Using 3% of H 2 O 2 Endogenous peroxidase on the tissue sections was blocked and incubated for 10min at room temperature.
(5) Taking out the dyeing rack, and pouring out H in the plastic dyeing vat 2 O 2 Adding tap water, placing into a staining rack, rinsing, slicing, and rinsing for 3 times, 10 times each time.
(6) And (3) circling: wiping the water around the tissue on the section with dust-free paper, drawing a circle around the tissue by an immunohistochemical pen, wherein the distance between the circle and the tissue is 2-3mm, and soaking the circled sheet in PBST.
(7) Primary antibody incubation: the sections were arranged in a wet box and primary antibody reagent, 3 drops/sheet, was added drop wise to the sections (depending on the section size, it is preferable to cover the section tissue completely). After incubation for 30min at room temperature, the sections were collected and rinsed 3 times in PBST for 10 washes each.
(8) Primary anti-post incubation: the sections were arranged in a wet box, wherein 2 drops/piece of primary anti-post reagent (artificial polypeptide-goat anti-mouse/rabbit antibody conjugate) were dropped on the sections of the experimental group (depending on the section size, it is preferable to completely cover the section tissue), and the control primary anti-post reagent (ImmunoHistoProbe, cat #1981-07, advanced-Biosystems) was dropped on the other sections, incubated at room temperature for 15-20min, and then the sections were collected and rinsed in PBST.
(9) And (3) secondary antibody incubation: the sections are arranged in a wet box, 2 drops/piece of a secondary antibody reagent (anti-human polypeptide monoclonal antibody-color reagent label-polymer) are dripped on the sections of the experimental group (the section size is suitable for completely covering the section tissues), and an enzyme-labeled polymer secondary antibody is dripped on the sections of the control group. After incubation for 15-20min at room temperature, the sections were collected and rinsed in PBST.
(10) DAB color development: and preparing fresh DAB color developing solution according to the required dosage. The sections were arranged in a wet box, 100. Mu.L/piece of DAB staining solution (preferably to cover the tissue of the section completely depending on the size of the section) was added dropwise to the sections, and the sections were developed for 1 to 5min (microscopic staining), and the development was stopped by rinsing with tap water. The sections were collected and rinsed in tap water.
(11) Hematoxylin counterstaining: the sections were placed in hematoxylin stain for 4min. Excess dye was removed by rinsing with tap water and then returned to blue in PBST solution for about 1min.
(12) Gradient alcohol dehydration, transparency and sealing.
(13) The staining results were observed under a microscope.
By using the above method, IHC detection was performed on different types of paraffin-embedded human tissue sections using the primary antibody post-reagent prepared in example 6 and the secondary antibody reagent prepared in example 7, respectively, in combination with specific primary antibodies, and the specific experimental protocol is shown in table 1:
TABLE 1 enhanced Secondary antibody IHC assay
The immunohistochemical staining results for esophageal tissue and tonsil tissue are shown in fig. 18 and fig. 19, respectively; the results of immunohistochemical staining of kidney tissue are shown in fig. 20; the results of immunohistochemical staining of thyroid tissues are shown in FIG. 21, respectively. The results show that the pathological secondary antibody detection kit and the method established by the artificial polypeptides PL, HM and LH and the antibodies thereof have stronger staining on esophagus, tonsil, kidney tissue and thyroid tissue than the control pathological secondary antibody detection kit and the method.
Example 9 Dual staining amplification of signals to identify tissue or cell types
The artificial polypeptide and the antibody thereof can also be used for double-antigen staining of tissue sections.
The protocol design for the double staining is shown in table 2:
TABLE 2 Dual staining amplification Signal identification of tissue or cell types
Taking a cervical cell slice (for simultaneously detecting p16 and Ki-67), placing the cervical cell slice in 95% ethanol, soaking and fixing for 30min, and then air-drying for later use. Paraffin-embedded prostate hyperplasia tissue sections (for simultaneous detection of p63 and CK 5) were deparaffinized and hydrated.
Antigen retrieval, primary antibody incubation, primary antibody post incubation, secondary antibody incubation, DAB staining and the like were performed using the method described in example 8. Except that after DAB staining, before hematoxylin counterstaining, AP visualization was performed: and preparing a fresh AP color developing solution according to the required dosage. The sections are arranged in a wet box, 100 mu L/piece of AP color development solution is dripped on the sections (the section size is suitable for completely covering the section cells), the color development is carried out for 5-10min (microscopic examination controls the dyeing), and the color development is stopped by flushing with tap water. The sections were collected and rinsed in tap water.
The result of double staining of cervical cell smear is shown in FIG. 22. In the figure, the cervical cytoplasm/nucleus stained by p16 is red stained, the cervical nucleus stained by Ki-67 is brown stained, and the result is positive, and the result is negative only when p16 or Ki-67 is stained or not stained. The results of double staining of prostate tissue are shown in FIG. 23. In the figure p63 stains the prostate epithelial cell nucleus, brown staining, and CK5 stains the prostate epithelial cytoplasm, red staining.
The results show that the detection system can be applied to double staining of pathological tissues and provide reference basis for clinical diagnosis.
Example 10 identification of tissue or cell types by triple staining
In this example, human kidney tissue sections were triple stained with COL4A1, PAX-8 and WT1, and the protocol is shown in Table 3.
TABLE 3 identification of tissue or cell types by triple staining
Human paraffin embedded tissue section kidney tissue 1 is selected for dewaxing and hydration. Antigen retrieval and the like were performed by the method described in example 8. Firstly, carrying out primary antibody incubation, primary antibody post-incubation and secondary antibody incubation by using the reagent of the 1 st group and the reagent of the 2 nd group; and then utilizing a reagent in group 3 to perform primary antibody incubation, primary antibody post-incubation and secondary antibody incubation, wherein the adding amount of the artificial polypeptide PL-goat anti-rabbit antibody conjugate needs to be excessive, so that the non-specificity of detection caused by the fact that part of the artificial polypeptide PL-goat anti-rabbit antibody conjugate is combined with COL4A1 antigen and rabbit source COL4A1 monoclonal antibody is combined with artificial polypeptide HM-goat anti-rabbit antibody conjugate which is added later because the artificial polypeptide PL-goat anti-rabbit antibody conjugate is not combined with the artificial polypeptide PL-goat anti-rabbit antibody conjugate is avoided.
After a second secondary antibody incubation, 1 drop of anti-fluorescence quencher (containing DAPI) was added dropwise to the sections, observed under a fluorescence microscope, and photographed. The triple fluorescent staining results are shown in FIG. 24, in which COL4A1 stains kidney tissue basement membrane as green fluorescence; PAX-8 stains renal tissue renal tubular epithelial cells, and the cell nucleus is yellow fluorescence; WT1 stained renal tissue glomerular epithelial cell nuclei in red.
Example 11 immunocytochemistry applications
Different cells were tested using immunocytochemistry assay, the protocol is shown in table 4:
TABLE 4 enhanced two-antibody immunocytochemistry assay
Cell wax blocks prepared from the corresponding cells were individually sectioned, deparaffinized, hydrated, and then stained as described in example 8.
As a result of the staining, raji cells (A) were stained brown in cell membrane after immunocyte staining using CD20 rabbit monoclonal antibody, as shown in FIG. 25. The cell nuclei of Daudi cells (B) and Hela cells (C) were stained brown after immunocyte staining using FoxP1 rabbit monoclonal antibody and Ki-67 rabbit monoclonal antibody, respectively.
The results show that the pathology enhanced secondary antibody consisting of the artificial polypeptides PL, HM and LH and the antibody thereof can realize the immunological staining of the cell wax block.
All documents mentioned in this application are incorporated by reference in this application as if each were individually incorporated by reference. Furthermore, it should be understood that various changes and modifications of the present invention can be made by those skilled in the art after reading the above teachings of the present invention, and these equivalents also fall within the scope of the present invention as defined by the appended claims.
Sequence listing
<110> Dian Ling (Hangzhou) Bio-pharmaceuticals, inc
<120> artificial polypeptide HM, antibody thereof and application thereof in pathological detection
<130> AJ2010226
<140> 202011455246.X
<141> 2020-12-10
<150> 202011402423.8
<151> 2020-12-02
<160> 48
<170> SIPOSequenceListing 1.0
<210> 1
<211> 6
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 1
Thr Thr Thr Pro Thr Thr
1 5
<210> 2
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 2
Thr Thr Thr Pro Thr Thr Pro Thr Thr
1 5
<210> 3
<211> 12
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 3
Thr Thr Thr Pro Thr Thr Pro Thr Thr Pro Thr Thr
1 5 10
<210> 4
<211> 15
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 4
Thr Thr Thr Pro Thr Thr Pro Thr Thr Pro Thr Thr Pro Thr Thr
1 5 10 15
<210> 5
<211> 18
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 5
Thr Thr Thr Pro Thr Thr Pro Thr Thr Pro Thr Thr Pro Thr Thr Pro
1 5 10 15
Thr Thr
<210> 6
<211> 21
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 6
Thr Thr Thr Pro Thr Thr Pro Thr Thr Pro Thr Thr Pro Thr Thr Pro
1 5 10 15
Thr Thr Pro Thr Thr
20
<210> 7
<211> 24
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 7
Thr Thr Thr Pro Thr Thr Pro Thr Thr Pro Thr Thr Pro Thr Thr Pro
1 5 10 15
Thr Thr Pro Thr Thr Pro Thr Thr
20
<210> 8
<211> 27
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 8
Thr Thr Thr Pro Thr Thr Pro Thr Thr Pro Thr Thr Pro Thr Thr Pro
1 5 10 15
Thr Thr Pro Thr Thr Pro Thr Thr Pro Thr Thr
20 25
<210> 9
<211> 30
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 9
Thr Thr Thr Pro Thr Thr Pro Thr Thr Pro Thr Thr Pro Thr Thr Pro
1 5 10 15
Thr Thr Pro Thr Thr Pro Thr Thr Pro Thr Thr Pro Thr Thr
20 25 30
<210> 10
<211> 33
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 10
Thr Thr Thr Pro Thr Thr Pro Thr Thr Pro Thr Thr Pro Thr Thr Pro
1 5 10 15
Thr Thr Pro Thr Thr Pro Thr Thr Pro Thr Thr Pro Thr Thr Pro Thr
20 25 30
Thr
<210> 11
<211> 15
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 11
Ala Ala Pro Ala Ala Asp Ala Ala Asp Ala Ala Pro Ala Ala Ala
1 5 10 15
<210> 12
<211> 21
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 12
Ala Ala Pro Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala
1 5 10 15
Ala Pro Ala Ala Ala
20
<210> 13
<211> 27
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 13
Ala Ala Pro Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala
1 5 10 15
Ala Asp Ala Ala Asp Ala Ala Pro Ala Ala Ala
20 25
<210> 14
<211> 33
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 14
Ala Ala Pro Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala
1 5 10 15
Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Pro Ala Ala
20 25 30
Ala
<210> 15
<211> 39
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 15
Ala Ala Pro Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala
1 5 10 15
Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala
20 25 30
Asp Ala Ala Pro Ala Ala Ala
35
<210> 16
<211> 45
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 16
Ala Ala Pro Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala
1 5 10 15
Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala
20 25 30
Asp Ala Ala Asp Ala Ala Asp Ala Ala Pro Ala Ala Ala
35 40 45
<210> 17
<211> 51
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 17
Ala Ala Pro Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala
1 5 10 15
Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala
20 25 30
Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Pro
35 40 45
Ala Ala Ala
50
<210> 18
<211> 57
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 18
Ala Ala Pro Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala
1 5 10 15
Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala
20 25 30
Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp
35 40 45
Ala Ala Asp Ala Ala Pro Ala Ala Ala
50 55
<210> 19
<211> 63
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 19
Ala Ala Pro Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala
1 5 10 15
Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala
20 25 30
Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp
35 40 45
Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Pro Ala Ala Ala
50 55 60
<210> 20
<211> 69
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 20
Ala Ala Pro Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala
1 5 10 15
Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala
20 25 30
Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp
35 40 45
Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala Ala Asp Ala
50 55 60
Ala Pro Ala Ala Ala
65
<210> 21
<211> 7
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 21
Gly Gln Ala Thr Ala Gln Gln
1 5
<210> 22
<211> 8
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 22
Gly Gln Ala Thr Thr Ala Gln Gln
1 5
<210> 23
<211> 9
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 23
Gly Gln Ala Thr Thr Thr Ala Gln Gln
1 5
<210> 24
<211> 10
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 24
Gly Gln Ala Thr Thr Thr Thr Ala Gln Gln
1 5 10
<210> 25
<211> 11
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 25
Gly Gln Ala Thr Thr Thr Thr Thr Ala Gln Gln
1 5 10
<210> 26
<211> 12
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 26
Gly Gln Ala Thr Thr Thr Thr Thr Thr Ala Gln Gln
1 5 10
<210> 27
<211> 13
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 27
Gly Gln Ala Thr Thr Thr Thr Thr Thr Thr Ala Gln Gln
1 5 10
<210> 28
<211> 14
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 28
Gly Gln Ala Thr Thr Thr Thr Thr Thr Thr Thr Ala Gln Gln
1 5 10
<210> 29
<211> 15
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 29
Gly Gln Ala Thr Thr Thr Thr Thr Thr Thr Thr Thr Ala Gln Gln
1 5 10 15
<210> 30
<211> 16
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 30
Gly Gln Ala Thr Thr Thr Thr Thr Thr Thr Thr Thr Thr Ala Gln Gln
1 5 10 15
<210> 31
<211> 5
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 31
Thr Asn Ala Met Ser
1 5
<210> 32
<211> 16
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 32
Ile Ile Ser Ser Ser Gly Ser Thr Tyr Tyr Ala Arg Trp Ala Lys Gly
1 5 10 15
<210> 33
<211> 3
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 33
Gly Asn Ile
1
<210> 34
<211> 12
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 34
Gln Ser Ser Gln Ser Val Tyr Asn Asn Asn Leu Ala
1 5 10
<210> 35
<211> 7
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 35
Arg Ala Ser Lys Leu Ala Ser
1 5
<210> 36
<211> 13
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 36
Leu Gly Gly Tyr Asp Cys Ser Ser Ala Asp Cys Gly Ala
1 5 10
<210> 37
<211> 5
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 37
Ser Tyr Ala Met Gly
1 5
<210> 38
<211> 16
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 38
Ile Ala Thr Thr Gly Ser Ser Thr Tyr His Ala Ser Trp Ala Lys Gly
1 5 10 15
<210> 39
<211> 11
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 39
Asp Gly Asp Trp Thr Gly Trp Tyr Phe Ser Ile
1 5 10
<210> 40
<211> 11
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 40
Gln Ala Ser Gln Ser Ile Ser Asn Arg Leu Ala
1 5 10
<210> 41
<211> 7
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 41
Asp Ala Ser Asp Leu Ala Ser
1 5
<210> 42
<211> 12
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 42
Gln Gln Gly Tyr Gly Gly Asp Asn Ile Glu Asn Leu
1 5 10
<210> 43
<211> 5
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 43
Arg Tyr Ala Met Cys
1 5
<210> 44
<211> 16
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 44
Ile Ile Gly Val Ser Gly Thr Thr Tyr Tyr Thr Ser Trp Ala Lys Gly
1 5 10 15
<210> 45
<211> 15
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 45
Val Met Pro Gly Tyr Asp Asp Tyr Gly Asp Asp Gly Phe Asp Pro
1 5 10 15
<210> 46
<211> 11
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 46
Gln Ala Ser Glu Asp Ile Tyr Ser Asn Leu Ala
1 5 10
<210> 47
<211> 7
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 47
Ala Ala Ser Tyr Leu Ala Ser
1 5
<210> 48
<211> 13
<212> PRT
<213> Artificial Sequence (Artificial Sequence)
<400> 48
Gln Cys Thr Tyr Tyr Ser Gly Ser Tyr Glu Leu Phe Thr
1 5 10
Claims (7)
1. The monoclonal antibody for resisting the artificial polypeptide HM is characterized in that the amino acid sequences of a heavy chain variable region CDR-H1, CDR-H2 and CDR-H3 and a light chain variable region CDR-L1, CDR-L2 and CDR-L3 of the monoclonal antibody are respectively shown in SEQ ID NO:37-42, wherein the amino acid sequence of the artificial polypeptide HM is AAPAADAAADAAPAAA.
2. A polymer conjugated with an antigen-binding portion of the mab of claim 1, and further conjugated with a visualization reagent.
3. The multimer of claim 2, wherein said chromogenic agent is selected from one of fluorescein, enzyme, metal ion, quantum dot, and isotope.
4. The multimer of claim 3, wherein said enzyme is selected from one of horseradish peroxidase, alkaline phosphatase, and β -glucosidase.
5. The use of the artificial polypeptide HM of claim 1 and the monoclonal antibody in the preparation of a kit for pathological examination, wherein the amino acid sequence of the artificial polypeptide HM is AAPAADAADAAPAAA.
6. A kit for pathological examination, comprising an artificial polypeptide HM-antibody conjugate in which the antibody is a polyclonal antibody and the amino acid sequence of the artificial polypeptide HM is AAPAADAAADAAPAAA, and the polymer of any one of claims 2 to 4.
7. A complex comprising a biological sample, a primary antibody, the artificial polypeptide HM-antibody conjugate of claim 6 and the polymer of any one of claims 2 to 4,
the antigen binding part of the monoclonal antibody on the polymer is combined with the artificial polypeptide HM, the polyclonal antibody on the artificial polypeptide HM-antibody conjugate is combined with the primary antibody,
the primary antibody binds to an antigen on the biological sample.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020114024238 | 2020-12-02 | ||
| CN202011402423 | 2020-12-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112694520A CN112694520A (en) | 2021-04-23 |
| CN112694520B true CN112694520B (en) | 2023-01-17 |
Family
ID=75508803
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202011455246.XA Active CN112694520B (en) | 2020-12-02 | 2020-12-10 | Artificial polypeptide HM, antibody thereof and application thereof in pathological detection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN112694520B (en) |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2544577C (en) * | 2003-12-01 | 2013-01-08 | Dako Denmark A/S | Methods and compositions for immuno-histochemical detection |
| CN103819538A (en) * | 2005-09-28 | 2014-05-28 | 加利福尼亚大学董事会 | Calcium binding peptides |
| US7897394B2 (en) * | 2006-09-21 | 2011-03-01 | Intrexon Corporation | Endoplasmic reticulum localization signals |
| JP5712513B2 (en) * | 2010-07-07 | 2015-05-07 | 富士レビオ株式会社 | Method for detecting human cytomegalovirus infection |
| BR112016029848A2 (en) * | 2014-06-24 | 2017-10-24 | Novo Nordisk As | mic-1 fusion proteins and uses thereof |
-
2020
- 2020-12-10 CN CN202011455246.XA patent/CN112694520B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN112694520A (en) | 2021-04-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9823251B2 (en) | Anti-Uroplakin II antibodies systems and methods | |
| US20160370370A1 (en) | Systems and Methods for Anti-PAX8 Antibodies | |
| JP4964957B2 (en) | Anti-drug antibody assay | |
| CN111566214B (en) | Anti-human IgG4 monoclonal antibody and human IgG4 assay reagent using same | |
| US11673969B2 (en) | Anti-biotin antibody and application thereof | |
| CN112694520B (en) | Artificial polypeptide HM, antibody thereof and application thereof in pathological detection | |
| CN112694521B (en) | Artificial polypeptide LH, antibody thereof and application thereof in pathological detection | |
| CN112694517B (en) | Artificial polypeptide PL, antibody thereof and application thereof in pathological detection | |
| CN112592385B (en) | Artificial polypeptide composition, antibody thereof and application thereof in pathological detection | |
| CN114874326B (en) | Monoclonal antibody for detecting estrogen receptor alpha, and preparation method and application thereof | |
| CN114874327B (en) | Monoclonal antibody for detecting progestational hormone receptor and preparation method and application thereof | |
| CN112834736B (en) | Pathological detection kit for detecting multiple antigens and preparation method and application thereof | |
| EP3306319B1 (en) | Test object detection method, and immunoassay instrument and monoclonal antibody for same | |
| US7148332B2 (en) | High affinity monoclonal antibody for recognizing the estrogen receptor (ER) and method for creating the antibody | |
| WO2001079266A1 (en) | Antibody against human kgfr | |
| WO2022202876A1 (en) | Immunological analysis method for type-i collagen c-terminal telopeptide | |
| Naseri et al. | APAAP complex: production and usage in immunocytochemical and immunohistochemical staining | |
| US7569675B2 (en) | High affinity monoclonal antibody for recognizing the progesterone receptor (PR) and method for creating the antibody | |
| CN104360057B (en) | A kind of ELISA reaction system detecting anti-CD 52 antibody and method | |
| TW202342979A (en) | Detection method and detection reagent | |
| CN117285636A (en) | First-antibody post-reagent and preparation method and application thereof | |
| KR100737230B1 (en) | Biosensor for Detection of ?-estradiol Having Anti-?-estradiol Antiserum and Detecting Process of ?-estradiol | |
| JP5585587B2 (en) | Method for immunological measurement of 5.9 kDa peptide | |
| CN116323670A (en) | Antibodies specific for alpha-1, 6-core-fucosylated PSAs and fucosylated fragments thereof | |
| Morrell et al. | and Nicholas R. Griffin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |